Follow PTCT's trial news. Pro members can get an alert when PTC Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 7% on Oct 30, a down day for the market: the S&P 500 fell 2%, 71% of stocks fell, and biotech stocks a median 2%.
| Holding it back | Sales down 43% on the year |
| Latest filing | 8-K, Oct 29 |
Mon Nov 16: Jefferies 17th Annual London Global…Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 4 reports it closed -0.4% on average, higher 2 of 4 times.
$2.2B in cash
No shelf registration or at-the-market program on file in the last three years.
Director Michael Schmertzler sold 2,500 shares on Oct 14, under a planned sale. 57 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
PTCT is #160 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 160 |
Share count against a year before: PTCT +6.2%, ZYME -3.1%, SDGR +1.8%, PTGX +3.8%.
Expected to report Thu Feb 18, after the close (in 108 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $357.8M, 70% more than a year ago; a loss of $0.62 a share.
PTCT's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Total revenue | $1.29B to $1.32B |
Sales grew 35% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 6% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Oct 29, 2026 | +0.5% | -7.0% | open |
| Jul 30, 2026 | -6.1% | -9.9% | -6.2% |
| May 7, 2026 | +14.9% | +14.3% | +12.8% |
Sales grew in six of the last seven years, to $1.7B in 2025. It turned a profit in 2025 after a loss in 2024.
4 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: PTCT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
“The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”
PTCT scores -2 today, which Breakaway calls Poor. It is #160 of 291 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 7% on Oct 30, a down day for the market: the S&P 500 fell 2%, 71% of stocks fell, and biotech stocks a median 2%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
PTCT scores -2 today, which Breakaway calls Poor (below zero). That is #160 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PTCT's -2.
Expected to report Thu Feb 18, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. PTCT closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.